Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study
Alexis Arzimanoglou, Jose A Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani, Alexis Arzimanoglou, Jose A Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani
Abstract
Objective: A good knowledge of safety and age group-specific pharmacokinetics (PK) of antiepileptic drugs (AEDs) in young pediatric patients is of great importance in clinical practice. This paper presents 6-month interim safety and PK from an ongoing 2-year open-label study (Study 303) of adjunctive rufinamide treatment in pediatric subjects ≥ 1 to < 4 years with inadequately controlled epilepsies of the Lennox-Gastaut syndrome (LGS) spectrum.
Methods: Subjects (N = 37) were randomized to either rufinamide or any other approved AED chosen by the investigator as adjunctive therapy to the subject's existing regimen of 1-3 AEDs.
Results: Interim safety results showed that treatment-emergent adverse events (TEAEs) were similar between the rufinamide (22 [88.0%]) and any-other-AED group (9 [81.8%]), with most events considered mild or moderate. A population PK analysis was conducted including plasma rufinamide concentrations from Study 303 and two other study populations of LGS subjects ≥ 4 years. The rufinamide PK profile was dose independent. The apparent clearance (CL/F) estimated from the PK model was 2.19 L/h; it was found to increase significantly as a function of body weight. Coadministration of valproic acid significantly decreased rufinamide CL/F. CL/F was not significantly affected by other concomitant AEDs, age, gender, race, hepatic function, or renal function. No adjustments to body weight-based rufinamide dosing in subjects ≥ 1 to < 4 years are necessary.
Significance: Rufinamide was safe and well tolerated in these pediatric subjects. Results from the interim analysis demonstrate that rufinamide's safety and PK profile is comparable in subjects ≥ 1 to < 4 and ≥ 4 years with LGS.
Clinical trial registration: Study 303 (clinicaltrials.gov: NCT01405053).
Keywords: Antiepileptic drug therapy; Infants; Lennox-Gastaut syndrome; Pharmacokinetic; Randomized study; Rufinamide; safety.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed